Your browser doesn't support javascript.
loading
Medication adversely impacts visually-guided eye movements in Parkinson's disease.
Munoz, Miranda J; Reilly, James L; Pal, Gian D; Verhagen Metman, Leo; Rivera, Yessenia M; Drane, Quentin H; Corcos, Daniel M; David, Fabian J; Goelz, Lisa C.
Afiliación
  • Munoz MJ; Department of Physical Therapy and Human Movement Sciences, Northwestern University, Chicago, IL, USA. Electronic address: mirandamunoz2022@u.northwestern.edu.
  • Reilly JL; Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
  • Pal GD; Department of Neurology, Rutgers University, New Brunswick, NJ, USA; Department of Neurological Sciences, Section of Parkinson Disease and Movement Disorders, Rush University Medical Center, Chicago, IL, USA.
  • Verhagen Metman L; Department of Neurological Sciences, Section of Parkinson Disease and Movement Disorders, Rush University Medical Center, Chicago, IL, USA.
  • Rivera YM; Department of Physical Therapy and Human Movement Sciences, Northwestern University, Chicago, IL, USA.
  • Drane QH; Department of Physical Therapy and Human Movement Sciences, Northwestern University, Chicago, IL, USA.
  • Corcos DM; Department of Physical Therapy and Human Movement Sciences, Northwestern University, Chicago, IL, USA.
  • David FJ; Department of Physical Therapy and Human Movement Sciences, Northwestern University, Chicago, IL, USA.
  • Goelz LC; Department of Physical Therapy and Human Movement Sciences, Northwestern University, Chicago, IL, USA; Department of Kinesiology and Nutrition, University of Illinois at Chicago, Chicago, IL, USA.
Clin Neurophysiol ; 143: 145-153, 2022 11.
Article en En | MEDLINE | ID: mdl-35995722
OBJECTIVE: We examined whether previous inconsistent findings about the effect of anti-Parkinsonian medication on visually-guided saccades (VGS) were due to the use of different paradigms, which change the timing of fixation offset and target onset, or different target eccentricities. METHODS: Thirty-three participants with Parkinson's disease (PD) completed the VGS tasks OFF and ON medication, along with 13 healthy controls. Performance on 3 paradigms (gap, step, and overlap) and 2 target eccentricities was recorded. We used mixed models to determine the effect of medication, paradigm, and target eccentricity on saccade latency, gain, and peak velocity. RESULTS: First, we confirmed known paradigm effects on latency, and target eccentricity effects on gain and peak velocity in participants with PD. Second, latency was positively associated with OFF medication Movement Disorders Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) motor score in PD. Third, medication prolonged latency for the larger target eccentricity across the 3 paradigms, while decreasing gain and peak velocity in the step paradigm across target eccentricities. CONCLUSIONS: Medication adversely affected and was not therapeutically beneficial for VGS. Previous inconsistencies may have resulted from chosen target eccentricity. SIGNIFICANCE: The negative medication effect on VGS may be clinically significant, as many activities in daily life require oculomotor control, inhibitory control, and visually-guided shifts of attention.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Parkinson Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Clin Neurophysiol Asunto de la revista: NEUROLOGIA / PSICOFISIOLOGIA Año: 2022 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Parkinson Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Clin Neurophysiol Asunto de la revista: NEUROLOGIA / PSICOFISIOLOGIA Año: 2022 Tipo del documento: Article
...